Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    Nkarta, Inc. (NKTX)

    1.5600 -0.1000 (-6.02%)
    At close: October 30 at 4:00:00 PM EDT
    1.6000 +0.0400 (+2.56%)
    After hours: October 30 at 7:17:59 PM EDT
    Trade Nkarta on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for NKTX
    • Previous Close 1.6600
    • Open 1.6600
    • Bid 1.1900 x 200
    • Ask 2.0400 x 200
    • Day's Range 1.5400 - 1.6600
    • 52 Week Range 1.5400 - 3.7200
    • Volume 1,211,807
    • Avg. Volume 739,510
    • Market Cap (intraday) 111.735M
    • Beta (5Y Monthly) 0.94
    • PE Ratio (TTM) --
    • EPS (TTM) -1.5800
    • Earnings Date (est.) Nov 10, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 10.83
    • Zacks Rating Neutral

    Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

    www.nkartatx.com

    106

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Nkarta, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    NKTX
    15.68%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    NKTX
    25.00%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    NKTX
    23.15%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    NKTX
    90.05%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -40.37M
    Profit Margin 0.00%

    Q2

    FY25

    Q3

    FY25

    Q4

    FY25

    Q2

    FY26

    -40M
    -30M
    -20M
    -10M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    9.00
    10.83 Average
    1.5600 Current
    14.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 8/14/2026
    Analyst Stifel
    Rating Action Maintains
    Rating Buy
    Price Action Lowers
    Price Target 11 -> 10
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -19.57%

    • Return on Equity (ttm)

      -38.76%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -117.32M

    • Diluted EPS (ttm)

      -1.5800

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      182.76M

    • Total Debt/Equity (mrq)

      29.68%

    • Levered Free Cash Flow (ttm)

      -55.13M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    ALXO
    PLRX
    BDTX
    CCCC
    FDMT
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: